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SECOND INTERNATIONAL WORKSHOP ON HELICOBACTER PYLORI
INFECTIONS IN THE DEVELOPING WORLD
Introduction
The Second International Workshop on Helicobacter pylori world who visit the developing world have been found to ac-
quire the infection, as would be expected if this form of trans-Infections in the Developing World was held at the Universidad
Peruana Cayetano Heredia in Lima, Peru, on 28–31 January mission occurs.
Means for diagnosis of H. pylori infection in the developing1996; participants from eight countries attended the workshop.
The First International Workshop on Helicobacter pylori Infec- world are not readily available. Endoscopy, biopsies, and cul-
tures are useful clinically, but these techniques are not applica-tions in the Developing World took place at the International
Center for Diarrhoeal Diseases Research, Bangladesh (ICDDR, ble for large population studies. New developments in instru-
mentation may make use of the C13 urea breath test moreB), in Dhaka, Bangladesh, on 2–4 February 1993 [1, 2]. The
workshop was an attempt to again bring together those persons readily available. Serology, which has been used widely for
diagnosis, requires reagents that are not always available anddirectly working in this field to discuss the latest research on
epidemiology, microbiology, diagnosis, and treatment of affordable. There is still the need for simpler noninvasive diag-
nostic assays, such as identification of the organisms in stool.H. pylori infection as it applies to developing countries.
It is now clear that infection with H. pylori is extremely The genetic characterization of strains of H. pylori from
developing countries is now under way; this characterizationcommon worldwide, particularly in developing countries
(where it occurs in most children and adults living in poor may lead to a better definition of virulence factors and should
make it possible to distinguish relapse from reinfection in per-socioeconomic conditions). It is also now clear that the patho-
logical lesions of gastritis in infected persons living in the sons who have been successfully treated for their infection but
reacquire it several months later.developing world are more severe than those in infected per-
sons living in the developed world. For these two reasons, we The pathophysiology of H. pylori infections has been exten-
sively studied in patients with all grades of gastritis, fromthought it was important to focus on this aspect of H. pylori
infections. chronic superficial gastritis to chronic deep gastritis to chronic
atrophic gastritis (which is accompanied by decreased gastricChildren in developing countries, such as Peru, Bangladesh,
and The Gambia, become infected at a very early age (often acid and is associated with intestinal metaplasia and dysplasia
and the development of gastric cancer). This progression ofwithin the first few months of life) and probably remain in-
fected throughout life. The pathology in infected adults living pathology has been thoroughly described by Peruvian scien-
tists. The high rate of chronic atrophic gastritis in Peru (aboutin these countries, however, may be markedly different. In
Peru, gastric cancer is very common and peptic ulcer is infre- 34% of adult patients are infected) does not seem to occur in
Bangladesh. Furthermore, Peruvians living at high altitudesquent, whereas in Bangladesh, peptic ulcer is common and
gastric cancer is infrequent. It is not presently known whether were found to have more severe gastric atrophy than Peruvians
living in coastal areas who had similar low socioeconomicthese differences are due to the host or to the bacterium. Differ-
ences in diet, including micronutrients such as selenium, have status. Further epidemiological studies are needed to determine
what other cofactors may be important in the development ofbeen postulated to account for these differences.
Infection is much more common in areas of poor sanitation. these lesions.
H. pylori is associated with peptic ulcer in developed coun-Whereas rates of reinfection are very high (up to 50% per
year) in developing countries, they are low (1% per year) in tries; therefore, one would expect an even higher rate of ulcer
disease in the developing world. Available reports, however,developed countries. Contaminated water seems to be the most
likely vehicle of transmission. Travelers from the developed show relatively low rates of peptic ulcer in rural Africa and
Peru.
Growth inhibition in young children who are infected with
H. pylori has been found in several developing countries. Fur-
This article is part of a series of papers presented at the Second International thermore, an increased rate of persistent diarrhea in Bangla-
Workshop on Helicobacter pylori Infections in the Developing World, held in deshi children has been found.Lima, Peru, in January 1996.
Many treatment schemes have been described that clearlyReprints or correspondence: Dr. R. Bradley Sack, School of Hygiene and
Public Health, Department of International Health, 550 North Broadway, Suite indicate that triple-drug therapy is distinctly superior to regi-
1001, Baltimore, Maryland 21205. mens with only two drugs. In some developing countries, how-
Clinical Infectious Diseases 1997;25:971–2 ever, drug resistance has become a problem, particularly resis-
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1058–4838/97/2505–0002$03.00 tance to metronidazole as found in Peru. Although treatment is
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tional, Astra/Merck, and Procter & Gamble (United States); andeffective in eradicating the organisms, reinfection is the major
Abbott and Glaxo Wellcome (Peru).concern in developing countries. Whereas rates of reinfection
in the United States (1%), Chile (3%), and Spain (3%) are low,
R. Bradley Sack, Klaus Gyr, and Raul Leon-Baruarates of reinfection in Peru within 1 year of treatment have
School of Hygiene and Public Health, Department of Internationalbeen reported to be nearly 90%. It may be possible through
Health, Johns Hopkins University, Baltimore, Maryland, USA;
immunization with H. pylori vaccines that are presently being Department of Internal Medicine, Kantonsspital Basel, Basel,
developed to prevent reinfection. Switzerland; and Universidad Peruana Cayetano Heredia, Instituto de
Medicina Tropical ‘‘Alexander von Humboldt,’’ Lima, PeruThe following series of articles represents about two-thirds
of the reports presented during the workshop.
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